NewAmsterdam Pharma Company N.V. (NAMS)
NAMS Stock Price Chart
Explore NewAmsterdam Pharma Company N.V. interactive price chart. Choose custom timeframes to analyze NAMS price movements and trends.
NAMS Company Profile
Discover essential business fundamentals and corporate details for NewAmsterdam Pharma Company N.V. (NAMS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Feb 2021
Employees
68.00
CEO
Michael Harvey Davidson FACC, Facp.,
Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Financial Timeline
Browse a chronological timeline of NewAmsterdam Pharma Company N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.41, while revenue estimate is $4.54M.
Earnings released on 6 Aug 2025
EPS came in at -$0.15 surpassing the estimated -$0.52 by +71.15%, while revenue for the quarter reached $22.43M , beating expectations by +541.97%.
Earnings released on 8 May 2025
EPS came in at -$0.49 falling short of the estimated -$0.45 by -8.89%, while revenue for the quarter reached $3.22M , beating expectations by +121.07%.
Earnings released on 26 Feb 2025
EPS came in at -$0.95 falling short of the estimated -$0.48 by -97.92%, while revenue for the quarter reached $13.23M , beating expectations by +653.31%.
Earnings released on 6 Nov 2024
EPS came in at -$0.18 surpassing the estimated -$0.48 by +62.50%, while revenue for the quarter reached $32.52M , beating expectations by +1.64K%.
Earnings released on 7 Aug 2024
EPS came in at -$0.51 surpassing the estimated -$0.59 by +13.56%, while revenue for the quarter reached $2.45M , beating expectations by +103.18%.
Earnings released on 8 May 2024
EPS came in at -$0.62 falling short of the estimated -$0.54 by -14.81%, while revenue for the quarter reached $1.51M , missing expectations by -7.03%.
Earnings released on 29 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$0.60 by +5.46%, while revenue for the quarter reached $1.75M .
Earnings released on 28 Feb 2024
EPS came in at -$0.54 surpassing the estimated -$0.55 by +1.82%, while revenue for the quarter reached $1.98M .
Earnings released on 7 Aug 2023
EPS came in at -$0.47 falling short of the estimated -$0.39 by -19.92%, while revenue for the quarter reached $1.72M .
Earnings released on 30 Jun 2023
EPS came in at -$0.52 falling short of the estimated -$0.44 by -17.25%, while revenue for the quarter reached $8.65M .
Earnings released on 31 Mar 2023
EPS came in at -$2.37 falling short of the estimated -$0.61 by -289.04%, while revenue for the quarter reached $1.49M .
Earnings released on 18 Oct 2022
EPS came in at -$2.14 , while revenue for the quarter reached $5.49M .
Earnings released on 30 Jun 2022
EPS came in at $1.61 , while revenue for the quarter reached $48.90M .
Earnings released on 30 Mar 2022
EPS came in at $1.70 , while revenue for the quarter reached $51.71M .
Earnings released on 31 Dec 2021
EPS came in at -$1.13 .
Earnings released on 30 Sept 2021
EPS came in at -$0.63 .
Earnings released on 30 Jun 2021
EPS came in at -$0.32 .
Earnings released on 31 Mar 2021
EPS came in at -$0.31 .
Earnings released on 31 Dec 2020
EPS came in at $0.00 .
Earnings released on 30 Sept 2020
EPS came in at -$0.02 .
NAMS Stock Performance
Access detailed NAMS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.